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10:30 
~ Different Callular Mach~nlams Account for 
Ventrlcular Dllatatlon In Is©hamlc and IdlopMhl¢ 
Dllafod (DEM) Human Haart FMlura 
R,R, Kaprtolian, P.A, Po01o.Wll~on, N,J, Sovom, Cnrdiac Mad'/leine, Iml.~Orl~ll 
Co l I~  ~chool of MediOino t~t Ntfflon~ll Haart & L~ng /nMitllte, London. UK 
«',a«kg~ound; Contmvemy oxlst~ au to 1110 contnbutlon of tncma~o in myoayto 
10ngth and relative sllppsgo el myo(:yles iù 1oft vontrlcular (LV) «hnmber 
dlletat;on and wall th'nnlng In end.staga human ho~trt fatlum. A mochnniem 
pur01y Involvtng incr,.»a~o in coll I~nglh would potontlally pm~~n/e normal 
my~Yt¢~ topograplly amd pnrmlt rovoralblllty of ventrlculm dilalalion, 
Motho~/»; Ht.lmen LV mvoc~sr(fltlm lrom ¢ontml (n = 4) and a~planted 
ond.Mage lalltng hoeda et pnllants wlll~ isd~emi¢ hand disoa~o (n .  51 er 
DeM (n =, 8) wom compamd Confo(~al mi~ms¢epy el tran~veraoly ~e(;tionnd 
tlt~~tle immuno,labolad tor conno~(in4~ was tmed 1o idonlily intnmalnlod iscs 
and (~011 pmlilos Thu propertler~ et total myoayto pmliles wtlh idonlitisbla 
di~cs is invemely proportional Ig (:oll Iongth, and thus provided an indirekt 
mo~stlm e! eorm~pondlng teil Ionglh, Valtlos wale exp[ossod relative to eon- 
trat tissne, Coll Iongth wan cormlntod wlth corm~ponding ochocn,diographtc 
m~~~ummonts et LV di;lm~te¢ (LVEDD), 
Ro~tltf~: Thoro was a ~tgnllicnnt inctm1180 el 50% in «~ll length in DCM, 
nllhotlgh them wn~ ne change In the lang dimension in myocytn~ In the 
cerl"ospoflcllflg tl~l~llO fmm lschllemic dilatnt; haarte (3% incmaso in toll 
IonWh); Knlskall-WNlls Tost p - 0,01, Rogmn~qon ~nnly,~Is el the psifed d[Ita 
et coll Ionglh and eerre~ponding LVEDD sho,,tod n streng co~mlallon i0 tl~o 
cn'~e o! DeM, wlth a samplo mgront~ion coolhciont (~) el 023%, p = 0,00~, 
n =~ 11, Them wa,~ no slgnlltaanl co[rotation ~r the ischemic cnKliomyopatl~lc 
ti,~sue; r ~ 33,0, p ~ 0377 (ns), n = 8, 
Conclasiens: These rt'~sults indicnte thnl =1 high pmporhon el vontncula¢ 
dtlotatton to DeM aan be nccountod tor by ~ncfoasod myocyte Iongth wdh 
minimal cell ,~lippt~go, Ih~u, urn~L lschomtc hen=la tailum occurs wllh minimal 
chnngo.~ in myocyto length ~uggostlng myocyto slippago as the prodominnnt 
mochsntsm, 
10:45 
~ ~  T Phe110110 Mutation Shows The Cardlac Troponln 
Phenotyplc Hetemgenelty and Benl9n Prognosls 
R An~n, H ~hono, A Kis~nuki, S Anma, S, Nakno, H. Tanaka, Kago.~h~m.1 
UntvPmff~~, K,%q~«hima, J~ll~n 
P~ckgtound: Familiat hypomophic a~iomvop.~thy (FHC) can be caused by 
a materien in the ca~iac tmpontn T (cTnT) gene. Stx mutntions in the cTnT 
gene (lle79Asn, Arg92GIn, A~g;Clrp, Alal04Val, AGlu160, Inlron15Gt • A) 
wem characton~."ed by high incidence el sudden doath, Howevor, clinical 
chemctorislics and prognosis of the Pho 110110 mutation am not known. We 
studied 6 lnmitios with the Pho110110 mulation in the cTnT gong. 
Methods: Fo~ly-six probands (24 males, 22 10malos, moan age 58 ~ 17 
y=s) with FHC ware screoned ler mntations in the cTnT gene The PI~ol10Ue 
mlssenso mtaobon was lound in 6 probands, The 6 familios wem analyzed 
gonotientty and clinically. Accon:ling to classiticalion et Mamn et al., distn- 
bution o! Ioft venlricular hypertrophy was classilied into type I, II, lU and IV. 
Knplnn-Meiro stlrvival Curve was constructed and compared with these el 
othor mutations. 
Resutts: Sixteen (5 males, 11 femalos, mean age 48 ~ 17 yrs) wem 
affected with the Phe 1101le mutation. Distributions el hypertrophy wem type 
II in 4, type III in 6 (1 with Ioll ventnctdar outtlow obstruction), type IV in 3. 
and nonpenetrance in 3. The distributions et hypedrophy ~atied wiihin each 
tamily, and among lamilies, Disease related death was seen in 2 individuals. 
The product-limit sun.,ival curve showod a benign prognosis with a survival 
signiticantly langer than the reported malignant cTnT mutations (P. 0.01). 
Concktsions: The Phe 1101le mutation in the cTnT gene show9 phenotypic 
heterogeneity and benign prognosis. 
11:00 
~Aaaoc la t lon  Potymorphlsms Manganose of of 
Suporoxldo Dismutase and Plasma 
Platelet-actlvatln9 Factor Acotylhydrolaao Genas 
Wlth Genetlc Susceptlbiilty to Non-fomilla! Dllated 
Cardlomyopathy 
S, tchlhnrn, Y, Ynmedn, M, Yokotn, Nngoyn Unlvomify Sclmol of M~ß~no, 
Nngoya, Jnp.~n 
B~ckgtound. Allhough aovoml gene,~ er genetia I~1 Ihet ¢!m responsible 
for, er contor ~u~geplibility o, famitinl d0ntod ca(diomyog~thy (L3CM) i~~0 
boen idontifiod, geneti~ dafo¢ts that undedie non,familial DeM mn~in to 
be chara¢tewi;~ed, Mico !a¢king m~nganese sgperoNide dismg!a~ (MnSOD) 
exhtbit DCM, euggosting the1 impairment o! the Oefense mechenisms against 
the oxidativo stmss is an impoRanl suscoptibility factor tot DCM- 
&~th¢~: WO studiod 158 heatthy incllvlduals and 93 patients w11h nen. 
tamilial DCM The asso¢iation of atleles el the Ms,aD and plasma platelet. 
n~tivating fa¢tor (PAF) acotylhydmlaso genas w0h non.famitial DeM bas new 
booo ~~westig~ted. 
Re-.stgt~: The lmquonctos et 1hg mutant T artete 01 ltm MnSOD gene ip = 
0.041 ; odds !atia, 1,9) and the muten1 m allelo (d the plasn~ PAF acetvIhy.- 
dmlase gene (p = 0.006; odds rollO, 1 9) wem signdicantty highe~ in J,.N~nese 
tndividn~gS with non,tamllial DCM Ihan in hoallhy conlwls. Com~ned ~n~ 
type anstysl~ mvoaled th~t the associatlon Ot the MnSOD TY and plasma 
PAF acetylhydrolsso mm er Atm genotvpes w0h DeM was h~jhly s~jnmcant 
(p = 0 000~, odds fatio, 3.1) 
Conclùsion: The polymolphtsms o1 the MnSQD and plasn~ PAF acehll. 
hydrot~so gongs am assoclatod wlth non4amilùd OCM in J~~,aneso and 
that these polymorphlsms m~v contnbuto to gonet¢ suscept~~hty to ttus 
condiben. 
11:15 
J8-8~~ Mark« Acceleration Of Caldiac Endo,helin-1 (ET-l) 
Expmuion  la Involved In Myoca~la l  Gmwth in B ie  
14,6 Syrlan Cardlomyopathlc  Hamster 
T Inod~, H Fuliv~'~~'a, M. A(aki, ~'.~. "ranaka, K. Hasegawa, S Sasayama 
K~'oto Univon~~~, Japan 
Backg«ound: ET-1 ts a patent vcsoconsthctivo and gmwth-Womotmg peptKle 
nnd mny be involvnd in the dovelopment o! socondan/ca~liae hyperlrophy. 
Wo havo pmviously r~p,,d,-d that the plasma ET-1 levels in hypertro~hm 
cardlomyopathy p~tients with normal pulmonan/hypetlenslon am elovatod 
and closely associatod with myoofle diameter in endomyoaa~rahat I~opsy 
spocimons. This study was aimed 1o ludhor clanly a rote of ET-1 in pnmanf 
myocardiat diseaso. 
Methode W~ mvostigated the tissuo loyal at ET-t us|ag specdm enzyme 
hnked tmmnoson/ant assay (ELISA) in Bie 146 Synan hamsteL~ (Bie) In 
this ELISA. cross«oactivity with big ET-t was less lhan 01%. In aOdaton. 
wo oxaminod the effoct o1 chronie tmatment with o~1 ET-1 type A receptor 
antagenist, T0201 on myocardial growth in this animal mndel. 
Re~ults: ET-t lovuls in Ioll veatncles wero not incroased in 5 weok-old 
(wo) Bie comparod with control F 113 hamster (F 1B). Howevet, the Iovels wem 
1.8-leid higher (p. 0.05) in 20 wo Bie and 6.4-told highor (p - 0.0001) in 35 
wo Bie than in F1B. Immunohistochemistw demonst~tnd that the elevatod 
Iovels el ET-1 is Iocahzed Io cardiac myocytes. T0201 inhibitnd the increase 
o1 the heart weight tHW) in Bie (Bie + vehide: 502 ~ 17 mg, Bie + T02.01: 
424 + 8 mg, p .  O.05L However, T0201 did not affect HW mcrease in FtB. 
Myocytes diameter was signdicantly smaller inT020t-lreated Bie 116.5 ~ 1.3 
~=m) than in vehicle-treated Bie (19.1 ~ 2.0 ùm)(p < 0005) 
Conc/usion: Marked acceleration of cardiac ET-1 express~on may be 
involved in myocardial grov.'th in this animal modal. 
11:30 
L -SB~ De Isolated Myocytes From the Remodeled Rat 
Infarct Haart Demonstrate Dlmlnished Contractile 
Response? 
A.J.C. Pmhash, S. Gupta, R. John. S.G Pandian. I.S. Anand. VA Med~cal 
Center. Minneapolis. MN. USA 
We hav~ re~ently shown that unloaded cardiae myocytes. 1mm the reinere 
non-infarcted, hypocontractile regions oi remodeled rat hearts, contract nor- 
mally. Since Ioad Is an important determinant o! contractile response, we 
investigated the elfects of viscous Ioading on the contractile tunction (video 
edge detection) of 268 myocytes isolated lrom the remodeled myocardium el 
infarcled (MI) rat hear($, (n = 7, 6 weeks Post-MI) and compared them with 
288 cells trom age matched sham operated hearls (Sham; n = 7). Viscosity 
of the myocyte suspension buffer was varied by adding inert methyl cellulose 
[4 mM Ca2+; 1, 15, 200 & 300 centipoise (cp)]. Buffer pedused MI hearts had 
JAC(' l:¢hnmD' l«~;~ 375A 
mgniflcantly dopmsr~~d global function (Langendodt LV devoloped pms«um 
46 Vs 113 mm Hg, p + 0,05), 
% Sholtenlm! tcp 1.5 Cp 200 cp ,3~ Cp 
,Sl~lm 07 ,05  ~ ] '4 .05  «~ 57103 ~ 24-*02' 
MI &;'~ 03 PO t 0.3 5? t03  36103 
V ~"enm0~ 
M! 7~t4  ~2t1 ;72=1 2()~I 
Not s~P, cam, " p , 005 Lmp~ee(l l.~=st ~ham Vs ML ! ~~ac~ty at ~ho,ffemr, g 
~4M.,"se¢, 
Oasal % myo~lte .sho~,~,m9 (1Cp) was not e~j~ticaùtly d#terent I~t~~en 
Sham ~nd MI ce~s (p = 0.08). A ~~k-Ae l~ndent  (~~~P--a~¢ wa~ aee~ in % 
~and~ols l~mShamandMl (p  ~ 00B*  M'4OVA). 
~ was no d ~ ~  m the myocy~ % ~ befween Sham and MI 
at 15cp & ~¢p (p = 03;' & (~ ~)  At ~ ep. MI m ~  conWaß,~e msponse 
was gmater than Sham O~JS (p - 0.01)- ~ v~scous Ioadm9 e~~lcanùy 
~e¢lreasel~ 5[~ßt~trell~n~ iß bo~ Sham & MI, Il UoeS not aflecl the 
MI ~ mo+e ~ .  "l'l~mefom, llhe global LV d,~sfunct~on seen m the 
remodeteO rat mla~ct mo(lisl may not be exp~amed by d~mm~shed contractùe 
mslxmse et the md~ù~fual myooßes flora the mmodeled myocammm 
11:45 
I ss7-61 Inhibition of Camitine S~/nthesis MO~~ 
Altet, ations in I~rotein ~ ls  of Saù:opiasmic 
Retk:ulum Ca~.Al"Pam and F.nzymes ~ With 
Glucose u lmzaUon in Rat l l~ ia l  ~ n  
K Yoneku'a ~ . Y. Eto ~ . "[ Aoya~ ~ . S. Momomma + , T. Krmoto ~, Y Hayash~ 2.
' The Se ind  Depmfr~m ot tùtemal Medrone, b~~mvemtty o  )~yo. To~y~ 
2Taß~~ Phatmaceut~cal Co*. Ud Tokusl~na. Japan 
Bac~~rouzx/- Decmase m Ca ~" ul:~ake of sarcol~asm¢ re~tum (SR) and 
cleemase m SR Ca ~'-ATPase (SERCA2) wo~n and mRNA fevels heve 
been ~~l:..ü~~c--d m pat~ents w~l  congest~e hearl fadure (CHF) d).m to vanous 
cafdmc dLsmdem. We Ixemously shewed that ml'ub~bon of cammne s ~  
by 3-{222-t~Jù~~hyl h~ruum)  ~ t e  (MET-88) pmtected Mft ven- 
tncular (LV) sys'tobc and d~astof¢ functmt~ ~r~ a~s wtth mTocar~al mfarcl~on 
(MI). In the cunent study we evaluated effects of i~'~hffmn of camdme s~nttte- 
SLS on protem levels et SERCA2 and se~eral enz~nes retated w~th gtuco~e 
ut]kzatmn. 
Meffmds: We induced MI m rats by f~atmg reh antenor cmscenchng com- 
na w arten/, and adr~~ed 100 moßg/day of ME1"-88 (MET-88 group) m 
l~acebo (MI group) fm 20 days, Shem group unOerwenl only cardmc ex- 
posme and rece~nd l~acebo. We measumd protem ~e ls  of SERCA2 and 
em'ymes re=ated wdh glucose u~~~zatmn *n ctuo~ LV myocardml h~na les  
by Weslem blo~t~J 
Resu~s. In crude LV myocam~al homogenate, SERCA2 p«ofem level was 
~-,duced by 32% [p - C.05) m MI group compared wsth Sham group In 
con~asL tt was m~nt3,n no..,m..~.= ,n MET-88 group. Among the enzymes 
retated wdh glucose uttl~zahon, ~~~~~jen syntase and hexokmase decrased 
by 41% and by 29% r~,e ly  in MI (p - 0.05). The reduc~on wem 
attenualed by the MET-88 treatment. SR fractmn showed qual~tabvely mr~tar 
results. 
Conctus~n: Inh~blbon of c/lr~tt~o ~mthests attenuated epressed protorn 
tevel et SERCA2. It moduMted these el en,.-ymes related wrth glucose ut~- 
hzabon, wh~ch may be tavorable for glucose utd~zat~on a d glycogen storage 
untier tschemlc condl1~on 
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10:30 
-~  The Preva lence  o f  Viable in 288 Myocard ium 
Pat ients With Congest ive  Heart  Fa i lure 
M Allen Auerbach. S. Yagoubi, S. Gambhir. 1". Simantov. M. Phelps. 
H. Scheibe;t, J. Czemin UCLA Schoof of Medicine. Los Angele& Cahfom~a. 
USA 
Background: The deteclion of myocardial viability is clinically impo'~ant for 
man~:~L;g patients (pts) wilh congestive heart failum (CHF). E.-C..~nsive areas 
of blood flow-metabofism mismatch (MM) by PET prediof tt,o recove~ of 
dysfunctional myocardium tollowing revasculadzation (CABG; functionally 
significant MM), while smafl areas of MM are associ«ted w~th an increased 
nsk ler cafOta¢ Ooath (progtx~tP_~ùy mgmtcant MM) Yet, the pmvatenco of 
myocardlal wablhty tn CHF pta remams unknown 
Metflod~: To Oetermme p~teac8  O1 n~/oca~~tat vla~ttTy chn~t N+13 
ammonlaJF.18 (!~owgt~os 0 PET stt.¢tm~ obtamed in ;288 CHF paTents 
(mean age: 62 ~ 10 yeam; mean LVEF L~ ¢ ~~) wem v~~ ~zeO 
tel presenc¢, (11 MM and match (M), The myo¢a~:~um was ~ Into 19 
Pe~t~' ,  prommat, r~ an¢i ~~tat Ix~ of the nnteno~ septum, a~,  
antemlateral, mfero~te~l, infenor and i n ~  walls imd ~x.  The LV 
¢t~mbet sLre wa~ Om(~~_ as severey, modemley, ~ ef~arged ~r 
MM was consKlemd "kmct~%!lly" s ~ m  d -5 segmenl~ (appmx. 25% 
O1 LV,myoca~kum) anc! "wognost¢alty" ~f¢ant  it «5 ~ wem 
mvolveO~ 
Resu/~ Fun¢l¢mally e~pnd¢,am MM o(:¢uùed fn 26% 0! pt~ wlth eeverety, 
26% wllh moOerately, 30% w~ md¢~/~ and 23% ~ normal LV m~e 
Ptognost*¢a!~, s~~ùf~ant MM o¢c~ned in 26% pts ~ sevem~y. 26% 
moderately, 30% wllh ffl*k~ erda~ and 33% w~~ Normal LV 
Conctus~ms: Rmc1~~atly and ~ l y  s~gn~l~ant amoums ol v~ù~e 
myocardmm occ~e m 26% and 21~- O1 unselected CHF pts retemed tel 
tll~ asses5ment o1 myo~ald~l v=abddy end fun¢tloß~ i ~ 1  fofim~n O
CABG can be expeofed in about 25% O1CHF pts. These wtth ~malle~ amoums 
of wabd~f rn~ght beneht pmgnom~ally from underg~ng revasculanzatmn. 
10:45 
~ ~ula~t ton  of Vlable Myocafdlum Favou~bly 
Influencu Len~ ~ ~ et Paùen~, Wllm 
Sev~re but Not ~ Iseheml¢ Left VeHdcular 
OysfuncUo. 
P+ Ma~,mo. CNR ms~u~e ot C~ca; P t~ok~,  P~~- On ~~tt  ot me VtP 
stu~; ~ Group Nuclear Card~Ax~ and Magne~ Reson~nce 
tnm~,~ Eteopean Sooerv ot Cart~o~. eaty 
Background: In pa~mnts w~th vanous degmes of tschem~c ler1 venmcular 
o~on.  Mlte is know about the ddferm~al effecl of comna~t revascular- 
tzat]on 
MeU'm~s: To tms atm, 22B patients (mean age 60 ~: 7 yrs) wtm prevz. 
ous myocardiad tnfarclmn, documented comnanj arten/dmease and mam- 
~ned ~a l~~ ur~emem corcmary revascuianza~on e~her by anomOamy or
surg~ aEfd IoTtg |ere1 foHow-up ~tLl~~t]Ofl. Doflltllartce Of 1~ VlablJlb/WaS 
deflned as a ~ned Tha~um-201 ul~ake m mine Ihan 50% of dysw~~- 
gm segments at res1 evaMatod in an anaton~,cai 11-segment model. C! Ih,e~e 
pat~x~s, 174 had a preoperalP,/e a n g ~  e j~ fracllon m the rarlge 
45-26% (Group I) and 54 ~ an ejec'lù:)n ~ ~25% (Group 2) Two 
ma~ched group of patents (group 3, 156 patmnts and group 4, 62 pat]ents) 
w~n the same electmn ~ ranges and vmb~lily/d~lunct~on mtm wem 
treated me~cafly The 4 groups dtd not differ wffh respecl to known deren'nr- 
nams et postmfarctmn pfognosts: ag(}, elec'bon fractmn, number of diseas,ed 
vessels and number of o'y~syner~c segments at rest. 
Results: tntraopefatnte mortalrty was 5% and 3% tn group 1 and 2, m- 
spectnmh/(p ns: The 48-month sunnval rafes wem not slat~sttcally d~ffefent 
in groups 1 and 3 cflaractenzed by an mferme~ale reduct;on of elect~n 
~ .  On the cor¢~ry, ~ ~ sunnval rates u=ere 92% and 72% m 
group 2 and 4 charactenzed by severe d ~ .  ~es~.,~.~tvely (p ~: 0.01). 
Conctustons. In patients wdh advanced mchemlc left venlncular dysfunc- 
tfon and dommance of tmsue vml:~l~~/, coronary revasculanzatmn s~n l ly  
mnproves k~~g-tetm ou~come and may ~ ~.~~-~~~t a rettable allematù/9 It:) hearl 
transp~nfat~n In pal~nts wdh moderafe d~sfunclmn, ~ 1  lherapy and 
cotonary ~ lanzatm'n  are ass(~aled wlth stmllar annual sunnval rates 
11:00 
~ Improved Exercise Per fo rmance  and Quallty o f  L i fe 
in Patlenls With Symptomatic Hypertensive Left 
Ventricular Hypertrophy by VDD Pacing: 
A Double-Bl ind Randomized  Cmss-over  Trtal 
O A. Kass. C-H. Chen, M Talbot, M. Nakayama. RS. KmvaL J Lima, 
Johns H,.~okms Un~=rsity. Batst.ere MD. USA 
B,3ckground Leff ventncular hy1~rtrophy (LVH) wùh chromc hy1~rtens~on 
may lead to exerttonat mtoleranco and congostwo heart fatture. Wo IeS1E'd 
the efficacy of chromc VDD pacmg, a proposed Iroatmenl for obsfru~we 
HCM. on thls seo0ndary fo:m ol LVH. 
Methods: Patmnts w~th LVH (NYHA-ltL 4-m. 5-1, artenal pressure: 160/92) 
on chrontc p and'er Ca 2" .l~ocker and diuretic thempy, recetved VDD pacmg 
w~th short AV delay to maiofam cont]nuouS HV aptcal preexcitalion. All had 
concentnc LVH (19 ± 0,6 mm wafl thlckness), and cavity oblilerat~on at rest 
er w~th dobutamine er Valsalva provocation. Pacmg was on er oft for lhe first 
3 mos. then switched for the next 3 mos in a randomized double-blind design. 
Exercise was stu~ied by treadmill-ergometr% 
ResultS: Maximal O~ consumpt~on (14.1 -- 1.0 BASE vs 16.7 ± 1.2 
pace-ON, p = 0.04, m 02/min~.g), 02 consumpt:cn, a1 anaerobic threshold 
